GlassScriptPhysician profile
Paarth Dodia
NPI 1508443532
$10,515.97
in general payments reported to CMS, 2019-2025
22 companies · $2,856 in 2025
The $2,856 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $444 · 2023: $2,597 · 2024: $4,619 · 2025: $2,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,868 · Education: $142 · Travel and Lodging: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,867.86 |
| Education | $141.99 |
| Travel and Lodging | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,435.93 | 2022-2025 | Skyrizi, Rinvoq, Humira |
| Ucb, INC. | $1,197.84 | 2023-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $1,083.29 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $1,062.69 | 2022-2025 | Ilumya, Blu-U, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $634.64 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $581.07 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $561.89 | 2024-2025 | |
| Genzyme Corporation | $426.93 | 2023-2025 | |
| Pfizer INC. | $343.17 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $296.98 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $271.99 | 2024-2025 | Olumiant, Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $259.51 | 2024-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $248.90 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $246.70 | 2023-2025 | Libtayo, Dupixent |
| Incyte Corporation | $204.87 | 2023-2025 | Opzelura, Opzelura |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $191.46 | 2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.16 | 2023-2025 | Spevigo |
| Convatec INC. | $137.19 | 2024 | |
| Leo Pharma INC. | $73.27 | 2025 | Adbry |
| Regeneron Pharmaceuticals, INC. | $49.57 | 2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.49 | 2025 | Cabtreo |
| Pharming Healthcare, INC. | $15.43 | 2025 | Ruconest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paarth Dodia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.